• 1
    Karlsson P, Dencker E, Nyberg S et al. Pharmacokinetics, dopamine D2 and Serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr. Res. 2006; 81 (Suppl.1): 8586.
  • 2
    Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007; 12: 904922.
  • 3
    Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 2008; 36: 769779.
  • 4
    Owen RT. Extended-release paliperidone: Efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today 2007; 43: 249258.
  • 5
    Arakawa R, Ito H, Takano A et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy inpatients with schizophrenia. Psychopharmacology (Berl) 2008; 197: 229235.
  • 6
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 7
    Guy W. Clinical Global Impressions. In: Guy W (ed.). ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD, 1976; 217222.
  • 8
    Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms. In: Yagi G (ed.). Commentary on the DIEPSS and Guide to Its Usage. Seiwa Publishers, Tokyo, 1996; 1160 (in Japanese).
  • 9
    Inada T, Yagi G, Gardos G. Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). Abstracts of 20th Collegium Internationale Neuropsycho-Pharmacologicum, Melbourne, Australia, 1996; 23–27.
  • 10
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics reliability and discriminative validity. Psychol. Med. 1983; 13: 177183.
  • 11
    Tzimos A, Samokhvalov V, Kramer M et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: A double-blind, placebo-controlled study with six-month open-label extension. Am. J. Geriatr. Psychiatry 2008; 16: 3143.
  • 12
    Schreiner A, Millet B, Rocca P et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone. Poster presented at the World Congress of Biological Psychiatry, 28 June–2 July 2009, Paris, France.
  • 13
    Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur. Neuropsychopharmacol. 2006; 16 (Suppl. 3): 149155.
  • 14
    Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medication. Can. J. Psychiatry 2006; 51: 480491.
  • 15
    Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int. J. Clin. Pharmacol. Ther. 2010; 48: 383399.
  • 16
    Berwaerts J, Cleton A, Rossenu S et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J. Psychopharmacol. 2010; 24: 10111018.
  • 17
    Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res. 1997; 6: 2126.
  • 18
    Johnson DA, Pasterski G, Ludlow JM, Street K, Taylor RD. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiatr. Scand. 1983; 67: 339352.
  • 19
    Kane JM. Schizophrenia. N. Engl. J. Med. 1996; 334: 3441.
  • 20
    Ohmori T, Ito K, Abekawa T, Koyama T. Psychotic relapse and maintenance therapy in paranoid schizophrenia: A 15 year follow up. Eur. Arch. Psychiatry Clin. Neurosci. 1999; 249: 7378.